Laboratory Industry Doesn't Forget COVID-19, But Shifts Focus to Other Health Conditions at AACC 2022 in Chicago
Retrieved on:
Thursday, July 28, 2022
LRE Map, Association, Legislation, Delta-8-Tetrahydrocannabinol, Ethics, Autonomous detection system, Pediatrics, Multimedia, University of Washington Department of Bioengineering, Roche, IVD, Siemens Healthineers, Professor, Warfarin, Acquisition, Genomics, Doctor of Philosophy, Research, NASH, Cancer, AACC, University of Missouri–Kansas City School of Medicine, Mayo, Automation, AI, NAFLD, COVID-19, Liver disease, DC-1, Liver, Blood, ELF, Kidney disease, Abbott, University, Beckman, Health informatics, Thermo Fisher Scientific, Hematology, GC, Clinical professor, Risk, TLA, American Association, Approximation error, Movement, Kidney, MD, FTIR, Patient, Department, LDT, Cirrhosis, Pharmaceutical industry, Medical device, Child, Mercy, Science, Personalized medicine
CHICAGO, July 28, 2022 /PRNewswire/ -- Urgent healthcare problems were addressed at the 2022 American Association for Clinical Chemistry (AACC) meeting of lab professionals and IVD vendors in Chicago.
Key Points:
- CHICAGO, July 28, 2022 /PRNewswire/ -- Urgent healthcare problems were addressed at the 2022 American Association for Clinical Chemistry (AACC) meeting of lab professionals and IVD vendors in Chicago.
- Kalorama Information analysts attended sessions and observed trends at the AACC meeting, noting that very little focus was related to the recent pandemic.
- Perhaps a vestige of the COVID-19 pandemic was a focus on better and faster workflows, automation and other products.
- AACC President Dr. Stephen R. Master, who himself served as an expert witness in Elizabeth Holmes' trial, moderated the discussion.